Related references
Note: Only part of the references are listed.Exploring the origin and regulatory role of mast cells in asthma
Ryan C. Murphy et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Eosinophilic and Noneosinophilic Asthma An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort
Liam G. Heaney et al.
CHEST (2021)
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study
P. Jane McDowell et al.
LANCET RESPIRATORY MEDICINE (2021)
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2021)
Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital
Hongwen Li et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2021)
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Eugene R. Bleecker et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
How can we minimise the use of regular oral corticosteroids in asthma?
Arnaud Bourdin et al.
EUROPEAN RESPIRATORY REVIEW (2020)
The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: A systematic review and meta-analysis
John Busby et al.
RESPIRATORY MEDICINE (2020)
Stratification of asthma phenotypes by airway proteomic signatures
James P. R. Schofield et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
Marjan Kerkhof et al.
THORAX (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Asthma and corticosteroids: time for a more precise approach to treatment
Eleanor M. Dunican et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Katherine N. Cahill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mepolizumab, quality of life, and severe eosinophilic asthma
Ian D. Pavord
LANCET RESPIRATORY MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation
A. R. Sousa et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2017)
Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma
Wanda Phipatanakul et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Cytokine-Induced Glucocorticoid Resistance from Eosinophil Activation: Protein Phosphatase 5 Modulation of Glucocorticoid Receptor Phosphorylation and Signaling
Konrad Pazdrak et al.
JOURNAL OF IMMUNOLOGY (2016)
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
Joan Sweeney et al.
THORAX (2016)
Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care
Merritt L. Fajt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry
Stephen O'Neill et al.
THORAX (2015)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A recommended analysis for 2 x 2 crossover trials with baseline measurements
Devan V. Mehrotra
PHARMACEUTICAL STATISTICS (2014)
Eosinophilic airway inflammation in nonallergic asthma
Guy G. Brusselle et al.
NATURE MEDICINE (2013)
Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates
James F. Donohue et al.
RESPIRATORY MEDICINE (2013)
Phenotypic predictors of response to oral glucocorticosteroids in severe asthma
Maciej Kupczyk et al.
RESPIRATORY MEDICINE (2013)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications
Raed A. Dweik et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma
Federico L. Dente et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2010)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Economic burden of asthma: a systematic review
Katayoun Bahadori et al.
BMC Pulmonary Medicine (2009)
Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-γ-inducible protein 10 expression in asthmatic airway mucosa
M Fukakusa et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
Refractory eosinophilic airway inflammation in severe asthma - Effect of parenteral corticosteroids
A ten Brinke et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
C Büttner et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways
MA Birrell et al.
RESPIRATORY RESEARCH (2003)
Share Paper
